Safety and tolerability of KarXT (xanomeline–trospium) in a phase 2, randomized, double-blind, placebo-controlled study in patients with schizophrenia

KarXT combines xanomeline, an M(1)/M(4) preferring muscarinic agonist with no direct D(2) receptor antagonism, with the peripherally restricted anticholinergic trospium. In EMERGENT-1 (NCT03697252), a 5-week, randomized, double-blind, placebo-controlled, phase 2 study in inpatients with schizophreni...

Descripción completa

Detalles Bibliográficos
Autores principales: Correll, Christoph U., Angelov, Angel S., Miller, Andrew C., Weiden, Peter J., Brannan, Stephen K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9719488/
https://www.ncbi.nlm.nih.gov/pubmed/36463237
http://dx.doi.org/10.1038/s41537-022-00320-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9719488/
https://www.ncbi.nlm.nih.gov/pubmed/36463237
http://dx.doi.org/10.1038/s41537-022-00320-1

Ejemplares similares